{"product_id":"tides-usa-oligonucleotide-peptide-therapeutics-2025","title":"TIDES USA Oligonucleotide \u0026 Peptide Therapeutics 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eTIDES USA Oligonucleotide \u0026amp; Peptide Therapeutics 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 3 videos + 1 pdf, size: 33.69 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: professionals in drug discovery, who focus on oligonucleotide, peptide, mRNA, and genome editing therapeutics\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-end=\"380\" data-start=\"60\"\u003eA translational, end-to-end program covering discovery, delivery, CMC, analytics, manufacturing, and clinical development for oligonucleotide and peptide drugs. Sessions convert cutting-edge science into practical playbooks for moving candidates efficiently from idea to IND and through the clinic.\u003c\/p\u003e\n\u003cp data-end=\"407\" data-start=\"382\"\u003e\u003cstrong data-end=\"405\" data-start=\"382\"\u003eWhat You Will Learn\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1344\" data-start=\"408\"\u003e\n\u003cli data-end=\"542\" data-start=\"408\"\u003e\n\u003cp data-end=\"542\" data-start=\"410\"\u003ePlatform selection \u0026amp; design: ASO\/siRNA\/miRNA\/mRNA\/saRNA vs. peptides\/peptidomimetics—chemistries, stability, and manufacturability\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"662\" data-start=\"543\"\u003e\n\u003cp data-end=\"662\" data-start=\"545\"\u003eDelivery strategies: LNPs, GALNAc, conjugates, depot and targeted systems; PK\/PD and biodistribution considerations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"773\" data-start=\"663\"\u003e\n\u003cp data-end=\"773\" data-start=\"665\"\u003eCMC \u0026amp; analytics: impurity control, sequence confirmation, potency\/stability assays, comparability, and QbD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"893\" data-start=\"774\"\u003e\n\u003cp data-end=\"893\" data-start=\"776\"\u003eProcess development \u0026amp; scale-up: solid-phase\/liquid-phase synthesis, hybrid approaches, purification and formulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1002\" data-start=\"894\"\u003e\n\u003cp data-end=\"1002\" data-start=\"896\"\u003eRegulatory \u0026amp; quality: IND\/IMPD expectations, ICH alignment, control strategies, and lifecycle management\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1109\" data-start=\"1003\"\u003e\n\u003cp data-end=\"1109\" data-start=\"1005\"\u003eNonclinical \u0026amp; clinical translation: models, safety\/pharm-tox, biomarkers, dose selection, trial design\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1219\" data-start=\"1110\"\u003e\n\u003cp data-end=\"1219\" data-start=\"1112\"\u003eOperations: raw-material sourcing, supply chain resilience, technology transfer, and cost-of-goods levers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1344\" data-start=\"1220\"\u003e\n\u003cp data-end=\"1344\" data-start=\"1222\"\u003eData \u0026amp; digital: sequence optimization, structure prediction, in-silico off-target analysis, and AI\/automation in analytics\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1365\" data-start=\"1346\"\u003e\u003cstrong data-end=\"1363\" data-start=\"1346\"\u003eEvent Details\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1680\" data-start=\"1366\"\u003e\n\u003cli data-end=\"1463\" data-start=\"1366\"\u003e\n\u003cp data-end=\"1463\" data-start=\"1368\"\u003eFormat: Plenary talks, parallel technical tracks, case studies, panels, posters, and exhibits\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1594\" data-start=\"1464\"\u003e\n\u003cp data-end=\"1594\" data-start=\"1466\"\u003eStructure: Discovery\/design → Delivery\/PKPD → CMC\/analytics → Manufacturing\/scale-up → Clinical\/regulatory → Commercialization\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1680\" data-start=\"1595\"\u003e\n\u003cp data-end=\"1680\" data-start=\"1597\"\u003eTakeaways: Checklists, templates, and benchmark metrics for immediate team adoption\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1934\" data-start=\"1682\"\u003e\u003cstrong data-end=\"1703\" data-start=\"1682\"\u003eWho Should Attend\u003c\/strong\u003e\u003cbr\u003eR\u0026amp;D scientists, CMC and QA\/QC leaders, process\/analytical chemists, formulation and delivery engineers, clinical and regulatory teams, manufacturing\/operations managers, BD and strategy leaders, platform founders, and investors.\u003c\/p\u003e\n\u003cp data-end=\"1952\" data-start=\"1936\"\u003e\u003cstrong data-end=\"1950\" data-start=\"1936\"\u003eWhy Attend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"2236\" data-start=\"1953\"\u003e\n\u003cli data-end=\"2047\" data-start=\"1953\"\u003e\n\u003cp data-end=\"2047\" data-start=\"1955\"\u003eReplace trial-and-error with validated development pathways for RNA and peptide modalities\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2139\" data-start=\"2048\"\u003e\n\u003cp data-end=\"2139\" data-start=\"2050\"\u003eAnticipate regulatory and manufacturing pitfalls early to de-risk timelines and budgets\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2236\" data-start=\"2140\"\u003e\n\u003cp data-end=\"2236\" data-start=\"2142\"\u003eBuild partnerships across discovery, CMC, and clinical teams to accelerate to proof-of-concept\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954522460258,"sku":"MED-AMB05249","price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/TIDES-USA-Oligonucleotide-Peptide-Therapeutics-2025.jpg?v=1779378822","url":"https:\/\/meducourse.com\/products\/tides-usa-oligonucleotide-peptide-therapeutics-2025","provider":"Meducourse","version":"1.0","type":"link"}